Long-Term Use of Actiq Safe and Effective for Breakthrough Pain

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 5
Volume 11
Issue 5

BALTIMORE-For cancer patients with breakthrough pain, oral transmucosal fentanyl (Actiq) continues to provide good relief with long-term use, Richard Payne, MD, said at the 21st Annual Scientific Meeting of the American Pain Society (abstract 770).

BALTIMORE—For cancer patients with breakthrough pain, oral transmucosal fentanyl (Actiq) continues to provide good relief with long-term use, Richard Payne, MD, said at the 21st Annual Scientific Meeting of the American Pain Society (abstract 770).

The study followed 156 outpatients who had completed double-blind, controlled trials of Actiq. The patients, from 32 centers, began Actiq at the same dose reached during successful titration and continued to use around-the-clock opioids for persistent pain, said Dr. Payne, of Memorial Sloan-Kettering Cancer Center.

Overall, the patients used more than 83,000 doses of Actiq to treat more than 77,000 episodes of breakthrough pain. During the first month of the study, patients reported a mean of 2.7 episodes per day, with 93% of episodes successfully treated with one Actiq dose. After 9 months, patients reported a mean of 3.8 daily episodes, and these were successfully relieved with a single Actiq dose 92% of the time. More than half of the patients (55%) required no dose escalation during the course of the study.

Using the 5-point Global Medication Performance scale, patients rated Actiq above "very good" throughout the study: 3.1 at 1 month to 3.2 at 9 months. The most common adverse events considered to be at least possibly related to Actiq use were nausea (10%), somnolence (9%), dizziness (8%), and vomiting (7%).

Dr. Payne and his colleagues concluded that "Actiq is an effective and well-tolerated treatment option for the long-term management of breakthrough pain. Patients rated Actiq’s performance at least very good regardless of its duration of use."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.